SciSparc Ltd. (NASDAQ:SPRC) received a 'buy' rating from Aegis Capital Corp. and a $20 price target Monday.

Yesterday, SPRC received a U.S. patent for 'Pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.' SPRC has received the same patent in Australia and Japan as well.

Last month, SPRC uplisted on the NASDAQ exchange bringing a full pipeline of clinical trials scheduled for its proprietary drug candidates. The Tel-Aviv-based company has steadily grown its patents worldwide for its core and unique technologies targeting conditions affecting the central nervous system.

SPRC stock traded above average volume, and the price was up after-market following the announcement of the previously mentioned U.S. Patent No. 11,207,290.

This represents the fourth patent SPRC has been awarded in the U.S.

SPRC's proprietary compounds and therapies including the latest patent are primarily targeted for treating disorders of the central nervous system. These include Tourette Syndrome, Sleep Apnea, Autism Spectrum Disorder, Pain and Epilepsy.

The aforementioned conditions comprise a nearly $30 billion market opportunity. The company's use of CBD amplifies the novelty of its therapies against its competition.

In a private placement last year, SPRC raised $8 million from institutional and accredited investors.

SPRC is a clinical stage biotechnology pharmaceutical company. The company specializes in CBD-based therapies and is on pace for a busy year according to their clinical trial schedule.

Drug Candidates Set Schedule For Clinical Trials

The Company is currently engaged in drug development programs for its portfolio of technologies and assets based on cannabinoid pharmaceuticals. Its drug candidates are:

SCI-110 for the treatment of Tourette Syndrome (TS) and Obstructive Sleep Apnea

SCI-160 for the treatment of pain

SCI-210 for the treatment of Epilepsy and Autism Spectrum Disorder (ASD)

For its leading drug candidate, SCI-110, SPRC already has supply chain infrastructure for the manufacturing and delivery of the drug.

SPRC Receives Patents In U.S., Australia and Japan

Adi Zuloff-Shani, PhD, and CTO of SPRC, says, "As an innovative pharmaceutical company, our IP portfolio is one of our greatest and most important assets. Obtaining a U.S. patent for our core technology constitutes a major achievement for us, especially as we are one of the few companies in the field that has IP protection on compounds and not only indications."

"We are pleased that the U.S. Patent and Trademark Office has again recognized the uniqueness of our compounds and methodologies and granted this patent."

"Our growing portfolio of patents is a testament to the dedication and innovation of the SciSparc team and strengthens our commitment to continue the work we do to bring therapies to patients suffering with the challenges associated with disorders of the central nervous system, for whom there is currently no effective treatment," he concludes.

It applies unique technologies through non-psychoactive cannabinoid pharmaceuticals.

Clinical Trial Outline:

The Company is making preparations for its SCI-110 IIb clinical trials for Tourette Syndrome. They will be conducted with the Hanover Medical School.

SPRC is preparing for Phase IIA clinical trials of SCI-110 for patients with AD and Agitation. They will be conducted with the approval of the Israeli Ministry of Health and Helsinki Committee.

Clinical trials will also be conducted by agreement with the Israeli Medical Center for Alzheimer's.

Pre-clinical studies will begin for evaluation of drug SCI-210 at The Sheba Fund for Health Services and Research. It is being evaluated for the treatment of Status Epilepticus

SPRC received necessary approvals from the Israeli Medical Cannabis Unit (IMCA) and the Ethical Committee.

SCI-160 tested positively for the treatment of neuropathic and post-operative pain. The controlled pre-clinical trial was conducted at the University of Calgary.

For more information, contact IR@scisparc.com

With all of these potential catalysts on the horizon, keep SPRC stock on your Watch List as it grows its patented IP portfolio.

Disclaimers: TopNewsGuide 'TNG', a Razor Pitch publication, is responsible for the production and distribution of this content. TNG is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by TNG is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall TNG. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by TNG., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. TNG. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. For some content, TNG., its authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. TNG has been compensated two thousand dollars via wire transfer by Adobe Global to produce and syndicate content for SciSparc Ltd. (SPRC). As part of that content, readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that can be found on our website.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

CONTACT: Mark McKelvie

mark@razorpitch.com

(754) 233-0966

.

(C) 2022 M2 COMMUNICATIONS, source M2 PressWIRE